MIM
ALT icon

MetLife Investment Management’s Altimmune ALT Stock Holding History

MetLife Investment Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$222K Buy
72,213
+34,020
+89% +$144K ﹤0.01% 2176
2025
Q4 		$138K Sell
38,193
-6,341
-14% -$27.6K ﹤0.01% 2458
2025
Q3 		$168K Sell
44,534
-2,336
-5% -$9.02K ﹤0.01% 2414
2025
Q2 		$181K Hold
46,870
– – ﹤0.01% 2246
2025
Q1 		$234K Buy
46,870
+2,396
+5% +$15.2K ﹤0.01% 2116
2024
Q4 		$321K Buy
44,474
+2,897
+7% +$22.1K ﹤0.01% 2035
2024
Q3 		$255K Hold
41,577
– – ﹤0.01% 2158
2024
Q2 		$276K Buy
41,577
+15,262
+58% +$113K ﹤0.01% 2044
2024
Q1 		$268K Hold
26,315
– – ﹤0.01% 2028
2023
Q4 		$296K Hold
26,315
– – ﹤0.01% 2012
2023
Q3 		$68.4K Hold
26,315
– – ﹤0.01% 2770
2023
Q2 		$92.9K Buy
+26,315
New +$118K ﹤0.01% 2723
2022
Q2 		– Sell
-21,184
Closed -$129K – 2857
2022
Q1 		$129K Buy
21,184
+8,385
+66% +$61.8K ﹤0.01% 2569
2021
Q4 		$117K Hold
12,799
– – ﹤0.01% 2351
2021
Q3 		$145K Hold
12,799
– – ﹤0.01% 2268
2021
Q2 		$126K Buy
+12,799
New +$175K ﹤0.01% 2383

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

MetLife Investment Management's ALT Position: Q1 2026 in Review

MetLife Investment Management increased its Altimmune (ALT) stake by 89% in Q1 2026, buying an estimated $144K and bringing the position to 72,213 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

MetLife Investment Management first reported a position in ALT in Q2 2021 and has held it in 16 quarters since. The position peaked at $321K in Q4 2024. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • MetLife Investment Management held 72,213 shares of Altimmune worth $222K as of Q1 2026.
  • MetLife Investment Management bought 34,020 Altimmune shares in Q1 2026, an estimated $144K.
  • Altimmune made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2176 holding.
  • MetLife Investment Management first reported a position in Altimmune in Q2 2021 and has held it in 16 quarters since.
  • MetLife Investment Management's Altimmune position peaked at $321K in Q4 2024.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.